AUBREY BODILY: Open Payments
NPI 1538701529 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$942 in 65 payments from 14 companies in 2025. Trend: 2023 $912 · 2024 $665 · 2025 $942
Food & beverage: $942
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $251 |
| Alkermes, Inc. | 10 | $185 |
| Janssen Pharmaceuticals, Inc | 4 | $92 |
| Teva Pharmaceuticals USA, Inc. | 3 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Corium, LLC | 2 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
Products named: VRAYLAR, ARISTADA, INVEGA SUSTENNA, AUSTEDO XR, FANAPT, LYBALVI, ABILIFY ASIMTUFII, REXULTI.
Industry payments across ID — which companies pay providers there.
